Inventor · disambiguated record
Tom Thuren
Also filed as: THUREN TOM
4 granted patents·11 pending applications·9 citations·filing 2011–2023
70Inventor score
Top patents by PatentIndex Score
15 records- 0177US10975145B2Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV eventNOVARTIS AG·Filed 2017·Granted Apr 13, 2021·1 cites·21 claims
- 0273US2024043525A1Use of canakinumabNOVARTIS AG·Filed 2023·Application pending·0 cites
- 0371US2022389090A1Use of il-1beta binding antibodiesNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0469US9683038B2Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV eventTHUREN TOM·Filed 2012·Granted Jun 20, 2017·3 cites·14 claims
- 0566US9061012B2Uses of DGAT1 inhibitorsMEYERS CHARLES·Filed 2011·Granted Jun 23, 2015·3 cites·5 claims
- 0664US2021317202A1Use of il-1 beta binding antibodies for treating peripheral arterial diseaseNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0763US10000565B2Use of IL-1 β binding antibodies for treating peripheral arterial diseaseBASSON CRAIG·Filed 2013·Granted Jun 19, 2018·2 cites·15 claims
- 0863US2021371512A1Use of IL-1 beta Binding AntibodiesNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0962US2023220063A1Il-1beta binding antibodies for use in treating cancerNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1061US2019048072A1USE OF IL-1beta BINDING ANTIBODIESNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1161US2020148759A1Use of il-1 beta binding antibodies for treating peripheral arterial diseaseNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1257US2020239564A1Use of canakinumabNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1354US2020199220A1Use of canakinumabTHURENS TOM·Filed 2018·Application pending·0 cites
- 1453US2018258166A1Use of il-1 beta binding antibodies for treating peripheral arterial diseaseNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1549US2021395737A1Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)NOVARTIS AG·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tom Thuren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →